PTRY

N/A

Report date: 2026/03/19 17:16:10

Base Information

Drug NamePTRY

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-Trophoblast glycoprotein +[5]

TargetsTrophoblast glycoproteinT cell surface glycoprotein CD3Programmed death-ligand 1

Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesChiome Bioscience Inc

China Registration ClassN/A

Develop Information

Active CompaniesChiome Bioscience Inc

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A